UnknownNCT01366183
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Vivian E von GruenigenGynecologic Oncology Group
- Intervention
- Assessment of Therapy Complications(procedure)
- Enrollment
- 290 enrolled
- Eligibility
- 75 years · All sexes
- Timeline
- 2011
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States
- Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- John Muir Medical Center-Concord Campus, Concord, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
- Saint Joseph Hospital - Orange, Orange, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- Olive View-University of California Los Angeles Medical Center, Sylmar, California, United States
- Rocky Mountain Gynecologic Oncology PC, Englewood, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01366183 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508306Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical MorbidityFaculty of Medicine of Tunis
- RECRUITINGPHASE1NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRegor Pharmaceuticals Inc.
- RECRUITINGPHASE1NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian CancerPhotonPharma, Inc.
- RECRUITINGPHASE1NCT07402915Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerAstraZeneca
- RECRUITINGPHASE2NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialUniversity of Michigan Rogel Cancer Center
- RECRUITINGNANCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsMayo Clinic
- RECRUITINGPHASE2NCT06971744Autophagy Maintenance (AUTOMAIN)Medical University of South Carolina
- RECRUITINGPHASE3NCT06963268Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)Instituto de Investigacion Sanitaria La Fe